Harte Hanks Enters Definitive Agreement to Be Acquired by Star Equity Holdings for $5.00 Per Share

Star Equity agreed to acquire Harte Hanks for $5.00/share, valuing the deal at $38.4 million in aggregate equity and representing an approximately 100% premium to Harte Hanks’ unaffected share price. Harte Hanks shareholders will receive 50% cash and 50% Star Equity 10% preferred stock. The Harte Hanks board unanimously approved the transaction and is recommending shareholder approval.

Analysis

This is more a capital-structure event than a strategic growth deal. For HHS holders, part of the headline premium is being rolled into a preferred instrument, so the economics are less certain than a pure cash takeout. That matters because it shifts duration and credit risk onto the seller side while giving STRR a way to finance with less immediate cash, but at the cost of adding a fixed charge that can cap the combined equity multiple.

The likely winner is STRR management if the deal closes without a balance-sheet stumble; they are effectively buying assets with a deferred claim rather than paying full cash. The loser set is existing STRR common holders if the market starts pricing in integration cost, preferred dividend burden, and a longer path to simplification. In these micro-cap structures, the second-order effect is usually multiple compression at the acquirer before any synergy re-rate, because liquidity and governance risk expand faster than operating synergies can be proven.

Near term, the trade is driven by closing probability and the mark-to-market on STRR, not by fundamentals. The contrarian risk is that investors treat this like a clean merger arb while the preferred leg behaves more like credit; any weak quarter, financing delay, or adverse preferred pricing can widen the spread quickly. If the implied value moves more than ~5% below $5 on STRR weakness, the market is signaling the deal is a balance-sheet trade, not a premium takeout.

Key Decisions for Investors

• Long HHS / short STRR common only if HHS still trades at a meaningful discount to $5 after adjusting for the preferred leg; target a 2-4% gross spread over 1-3 months, with the trade invalidated if STRR stabilizes and HHS closes above $4.90.
• If borrow is tight, avoid forcing the short: buy HHS only as a low-beta event arb and hedge broad market risk with index futures rather than paying up for STRR borrow.
• Fade STRR post-announcement strength into the close; this looks more like financing accretion than operating value creation, so any rally above the pre-deal range is a candidate for mean reversion over 2-6 weeks.
• Watch STRRP relative pricing around the deal date; a sharp discount would be a tell that the market is demanding a higher yield for the preferred layer and is questioning the combined balance sheet.